FZ-AD004 / Shanghai Fudan-Zhangjiang - LARVOL DELTA

Dose-escalation results from a phase I study of FZ-AD004, a TROP2-directed ADC, in patients with advanced solid tumors. (ASCO 2026) - P1 | "FZ-AD004 demonstrated a manageable safety profile with no DLTs observed up to 12.0 mg/kg and promising antitumor activity in heavily pretreated NSCLC patients, particularly at doses of 8.0 and 10.0 mg/kg. These doses are being further explored in the expansion phase. Clinical trial information: NCT 05914545."

ADC • Clinical • First-in-human • Metastases • P1 data • Dental Disorders • Keratitis • Lung Cancer • Non Small Cell Lung Cancer • Ocular Inflammation • Oncology • Ophthalmology • Solid Tumor • Stomatitis • EGFR • KRAS

A Study of FZ-AD004 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=121 | Recruiting | Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

First-in-human • Trial completion date • Trial primary completion date • Solid Tumor

A Study of FZ-AD004 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=121 | Recruiting | Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor